Hepatitis B (recombinant) vaccine (Invac B (1 ml)) is an immunizing agent, used to prevent hepatitis B infection. It stimulates the body to produce antibodies against hepatitis B infection. The ...
Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1. INVAC-1 is an innovative therapeutic DNA vaccine, which specifically targets ...
A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity. This is an ASCO Meeting Abstract from the 2019 ASCO ...
French startup Invectys hopes its cancer vaccine can win a spot in immuno-oncology combination therapies, and it just nabbed €15 million ($17 million) in series A funding to support that ambition. The ...
A phase I study of novel multi-HLA-binding peptides and a new combination of immune adjuvants against solid tumors. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract ...
Hepatitis B (recombinant) vaccine (Invac B) is an immunizing agent, used to prevent hepatitis B infection. It stimulates the body to produce antibodies against hepatitis B infection. The information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results